- Details
- Andrea Miyahira hosts a discussion with Veda Giri, Ayesha Shafi, and Claire Fletcher, members of the PCF Women in Science Forum Organizing Committee. The forum aims to build a strong network of women in prostate cancer research and address gender inequities in science. Key themes include negotiation strategies for women, with insights from law professor Stacy Lee; amplifying women's voices in rese...
|
- Details
- Patrick Pilié discusses his team's paper on SPOP mutations in prostate cancer and their therapeutic vulnerabilities, especially to PARP inhibitor-induced growth suppression. The paper, published in Clinical Cancer Research, explores the heterogeneous nature of prostate cancer treatment responses, particularly in metastatic castrate-resistant prostate cancer with SPOP mutations. These mutations sho...
|
- Details
- Andrea Miyahira engages with Scott Dehm to discuss his research on AR gene alterations in endocrine therapy-resistant prostate cancer. In collaboration with teams from multiple universities, including Princeton and UCSF, Dr. Dehm examines the frequent AR gene alterations in castration-resistant prostate cancers. Utilizing linked-read DNA sequencing, the study confirms that a subset of these cancer...
|
- Details
- Andrea Miyahira engages with Akash Patnaik on his team's research on tumor cell lactate-generating signaling pathways in aggressive-variant prostate cancer. Dr. Patnaik highlights the challenges associated with treating PTEN deficient prostate cancers, which constitute about 50% of metastatic castrate-resistant prostate cancer cases resistant to standard treatments. His research emphasizes the rol...
|
- Details
- Zach Klaassen speaks with Andrea Miyahira about the Prostate Cancer Foundation’s (PCF) significant contributions to the development of PSMA theranostics in prostate cancer. Celebrating its 30th anniversary, PCF has invested over $30 million in PSMA-related research, leading to FDA-approved imaging agents and therapies like Pluvicto. Dr. Miyahira outlines the foundation's future focus, including fu...
|
- Details
- Zach Klaassen hosts a discussion with Thomas Hope Jeremie Calais about a conference co-hosted by UCLA and UCSF, focusing on PSMA PET imaging and radioligand therapy. Scheduled for January 18th and 19th, 2024, at UCSF, the conference aims to educate healthcare professionals on interpreting PSMA PET results and managing patients effectively. The target audience includes both academic and private pra...
|
- Details
- Alicia Morgans interviews Rana McKay about the upcoming second Annual Prostate Cancer Patient Summit at UCSD in February 2024. The summit, a collaboration between UCSD and the Prostate Cancer Foundation, aims to be a dynamic forum for patients, caregivers, and anyone interested in prostate cancer. The event will feature a community think tank to address unmet needs in prostate cancer research. Reg...
|
- Details
- Tamara Jamaspishvili delves into her group's study on PTEN loss as an early predictor of prostate cancer metastasis post-surgery. The study employs artificial intelligence to enhance the accuracy of PTEN loss assessment, traditionally done manually by pathologists. Dr. Jamaspishvili explains that PTEN, a tumor suppressor gene, is a critical biomarker for aggressive prostate cancer. Her team's AI-b...
|
- Details
- In this conversation, Andrea Miyahira hosts Gerhardt Attard to discuss a publication in Nature Communications, specifically focusing on the genomic architecture of lethal prostate cancer clones. The study from Dr. Attard’s team examines alterations in the androgen receptor (AR) and their association with resistance to treatments like abiraterone and enzalutamide. Dr. Attard highlights the intrapat...
|
- Details
- Amina Zoubeidi delves into her research on prostate cancer lineage plasticity. She highlights her team’s paper, "ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer," published in Cell Reports. Dr. Zoubeidi explains the concept of lineage plasticity and its role in therapy resistance, particularly post-hormone therapy. She introduces th...
|
